Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PCSK9 Inhibitors May Feel Effects Of FDA Judgment On IMPROVE-IT

Executive Summary

Agency's decision on cardiovascular risk reduction claims for Merck's Zetia and Vytorin may serve as a regulatory barometer for the magnitude and robustness of effect that will be expected in outcomes studies for other LDL-C-lowering agents.


Related Content

Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?
Where Cholesterol Surrogates Stand After ACC '16
PCSK9 Sponsors, Payers In The Ring At ACC
Does Esperion's Plan For A Statin-Intolerant Claim Have A Shot?
Praluent Sponsors Set Tone For PCSK9 Labeling, Post-Marketing Negotiations
IMPROVE-IT Study: Negative Panel Review Leaves FDA With Tough Choice
Merck's IMPROVE-IT: FDA Panel Review Has Implications Beyond Zetia, Vytorin
PCSK9 Mechanism Lends Confidence Ahead Of Outcomes Data
New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials
Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts